| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| P656169-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $440.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC 50 value of 49 nM and 135 nM on rhesus and human M1 receptor , respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease In Vivo PQCA (3-30 mg/kg; oral administration; single- or pair-housed male rhesus monkeys) treatment attenuates the scopolamine deficits in PAL and CPT tasks. Blockade of muscarinic signaling by scopolamine produces significant impairments in both tasks . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Ten single- or pair-housed male rhesus monkeys (6-10 years old; 5.2-10.5 kg) with scopolamine Dosage: 3 mg/kg, 10 mg/kg, or 30 mg/kg Administration: Oral administration Result: Attenuated the scopolamine deficits in paired-associates learning (PAL) and the continuous-performance task (CPT). IC50& Target:EC50: 49 nM (Rhesus M1 receptor) and 135 nM (Human M1 receptor) |
| Canonical SMILES | C1CN(CCC1(C#N)C2=CC=CC=N2)CC3=C4C=CC=CN4C(=O)C(=C3)C(=O)O |
|---|---|
| Molecular Weight | 388.42 |
Enter Lot Number to search for COA:
